Select Language
JAK1
JAK1 Overview
| English Name | Tyrosine-protein kinase JAK1 | Approved Drugs | 13 |
| Drugs in Clinical Trials | 46 | Target Synonym | JAK1B，Tyrosine-protein kinase JAK1，JAK1，Janus Kinase 1，JAK1A，EC 2.7.10.2，JAK-1，JTK3，EC:2.7.10.2，EC 2.7.10 |
| Highest Development Stage | Approved | ||
| English Name | Tyrosine-protein kinase JAK1 |
| Target Synonym | JAK1B，Tyrosine-protein kinase JAK1，JAK1，Janus Kinase 1，JAK1A，EC 2.7.10.2，JAK-1，JTK3，EC:2.7.10.2，EC 2.7.10 |
| Approved Drugs | 13 |
| Drugs in Clinical Trials | 46 |
| Highest Development Stage | Approved |
JAK1 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
JA1-H5547 |  Human | InsectCells | Human JAK1 Protein, His Tag |  |  |
Total: 1
- 1
JAK1 Background
JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. It interacts with the common gamma chain (γc) of type I cytokine receptors, to elicit signals from the IL-2 receptor family (e.g. IL-2R, IL-7R, IL-9R and IL-15R), the IL-4 receptor family (e.g. IL-4R and IL-13R), the gp130 receptor family (e.g. IL-6R, IL-11R, LIF-R, OSM-R, cardiotrophin-1 receptor (CT-1R), ciliary neurotrophic factor receptor (CNTF-R), neurotrophin-1 receptor (NNT-1R) and Leptin-R). Jak1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body
JAK1 Synonyms
JAK1,JAK-1,JAK1A,JAK1B,Jak1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Povorcitinib | INCB54707; INCB-54707; INCB054707; INCB-054707 | Phase 3 Clinical | Incyte Corp | Angioedema; Asthma; Chronic Urticaria; Hidradenitis Suppurativa; Kidney Diseases; Prurigo Nodularis; Pruritus; Renal Insufficiency; Urticaria; Vitiligo | Details |
| WXFL-10203614 | WXFL-10203614 | Phase 3 Clinical | Wuxi Apptec Co Ltd, Wuxi Fuxin Pharmaceutical Research And Development Co Ltd | Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic | Details |
| TLL-018 | TLL-018 | Phase 3 Clinical | Tll Pharmaceutical Llc | Arthritis, Rheumatoid; Chronic Urticaria; Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Urticaria | Details |
| Pumecitinib | PG-011 | Phase 3 Clinical | Prime Gene Therapeutics Co Ltd | Rhinitis, Allergic; Rhinitis, Allergic, Seasonal | Details |
| Ruxolitinib (Taro Pharmaceuticals) | Phase 3 Clinical | Taro Pharmaceuticals Usa Inc | Dermatitis, Atopic; Hidradenitis Suppurativa | Details | |
| Ruxolitinib Gel(Hangzhou Zhongmei Huadong) | HDM3010; HDM-3010 | Phase 3 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Prurigo Nodularis; Vitiligo | Details |
| BHV-8000 | TLL-041; TLL041 | Phase 3 Clinical | Hangzhou Highlightll Pharmaceutical Co Ltd | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Central Nervous System Diseases; Parkinson Disease | Details |
| LW-402 | LW-402 | Phase 3 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic; Inflammatory Bowel Diseases; Spondylitis, Ankylosing; Vitiligo | Details |
| VVN-461 | VVN461LD; VVN-461; VVN461e; VVN-461-e | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Inflammation; Postoperative inflammation; Uveitis; Uveitis, Anterior | Details |
| Quecitinib | QY201; QY-201 | Phase 3 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Dermatitis, Atopic; Prurigo; Prurigo Nodularis; Psoriasis; Spondylitis, Ankylosing; Vitiligo | Details |
| VC-005 | VC-005 | Phase 3 Clinical | Jiangsu Vcare Pharmatech Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Eczema; Inflammatory Bowel Diseases; Joint Diseases; Spondylitis, Ankylosing; Vitiligo | Details |
| Zemprocitinib | LNK01001; LNK-001; LNK001; LNK-207; EQ-121; LNK-01001 | Phase 3 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic; Spondylitis, Ankylosing | Details |
| WXSH-0150 | WXSH-0150; TUL-01101 | Phase 2 Clinical | Zhuhai United Laboratories Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic | Details |
| NS-229 | NS-229 | Phase 2 Clinical | Neurosearch As | Eosinophilic Granulomatosis With Polyangiitis; Epilepsy | Details |
| Ivarmacitinib sulfate Base gel(Jiangsu Hengrui Medicine) | SHR0302 base | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Vitiligo | Details |
| Tofacitinib citrate (CAGE Bio) | CGB-500; CGB-501 | Phase 2 Clinical | CAGE Bio Inc | Alopecia Areata; Dermatitis, Atopic | Details |
| ALY-101 | ALY-101 | Phase 2 Clinical | Alys Pharmaceuticals Inc | Alopecia Areata; Dermatitis, Atopic; Eczema | Details |
| TDM-180935 | TDM-180935 | Phase 2 Clinical | Jiaxing TechnoDerma Medicines Inc | Dermatitis, Atopic | Details |
| AC-201 | AC-201 | Phase 2 Clinical | Accro Bioscience (Suzhou) Co Ltd | Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Uveitis | Details |
| H-018 | H018; H-018 | Phase 2 Clinical | Jiangsu Carephar Pharmaceutical Co Ltd, Nanjing Shenzhou Jiamei Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic; Vitiligo | Details |
| Fingolimod/Tofacitinib | FMX-114 | Phase 2 Clinical | Vyne Therapeutics Inc | Dermatitis, Atopic | Details |
| JYP-0061 | JYP-0061 | Phase 2 Clinical | Guangzhou Jiayue Pharmaceutical Technology Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Autoimmune Diseases; Demyelinating Diseases; Dermatitis, Atopic; Neuromyelitis Optica; Prurigo Nodularis; Spondylarthritis; Vitiligo | Details |
| Londamocitinib Xinafoate | AZD-4604 | Phase 2 Clinical | Astrazeneca Plc | Asthma | Details |
| Lepzacitinib | Phase 2 Clinical | Aclaris Therapeutics Inc | Dermatitis, Atopic | Details | |
| LNK-01002 | LNK01002; LNK-1000318 | Phase 2 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential | Details |
| Itacitinib | INCB-039110-adipate; INCB-39110; INCB-039110; IBI-377 | Phase 2 Clinical | Incyte Corp | Arthritis, Rheumatoid; Asthma; Bone Marrow Neoplasms; Breast Neoplasms; Bronchiolitis Obliterans; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chondrosarcoma; Colitis, Ulcerative; Colorectal Neoplasms; Cytokine Release Syndrome; Endometrial Neoplasms; Graft vs Host Disease; Head and Neck Neoplasms; Hematologic Neoplasms; Hemic and Lymphatic Diseases; Hodgkin Disease; Leiomyosarcoma; Leukemia; Leukemia, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Plasma Cell; Leukemia, Prolymphocytic, T-Cell; Liposarcoma; Liposarcoma, Myxoid; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Plaque psoriasis; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia- | Details |
| Elsubrutinib/Upadacitinib | ABBV-599 | Phase 1 Clinical | Abbvie Inc | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
| CS-12192 | CS12192 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Alopecia Areata; Autoimmune Diseases; Dermatitis, Atopic; Enteritis; Graft vs Host Disease; Lupus Erythematosus, Systemic; Multiple Sclerosis | Details |
| FZJ-003 | FZJ-003 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic | Details |
| Frevecitinib | VR-588; KN-002; KN-002 (Kinaset Therapeutics/Vectura) | Phase 1 Clinical | Vectura Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| GLPG-3121 | GLPG-3121 | Phase 1 Clinical | Galapagos Nv | Details | |
| tofacitinib (3S Bio) | SSS-32 | Phase 1 Clinical | 3sbio Inc | Arthritis, Rheumatoid | Details |
| LP-0184 | LP-0184 | Phase 1 Clinical | Leo Pharma A/S | Dermatitis, Atopic | Details |
| Tofacitinib(Biora Therapeutics) | BT-600; PGN-600 | Phase 1 Clinical | Progenity Inc | Colitis, Ulcerative | Details |
| HHT-109 | HHT-109 | Phase 1 Clinical | Zhejiang Huahai Pharmaceutical Co Ltd | Arthritis, Rheumatoid | Details |
| Tofacitinib Citrate Modified-Release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Arthritis, Rheumatoid | Details | |
| Abrocitinib Oral Suspension(Pfizer) | Phase 1 Clinical | Pfizer Inc | Dermatitis, Atopic | Details | |
| Tofacitinib citrate (TWi Biotechnology) | IMG 003; AC-1101 | Phase 1 Clinical | Twi Biotechnology Inc | Granuloma Annulare | Details |
| Tofacitinib controlled release (Triastek) | T-21; T21; T-19 | Phase 1 Clinical | Triastek Inc | Arthritis, Rheumatoid | Details |
| GDC-0214 | RG-6151; GDC-0214 | Phase 1 Clinical | Genentech Inc | Asthma | Details |
| QY-211 | QY211; QY-211 | Phase 1 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Dermatitis, Atopic; Eczema; Vitiligo | Details |
| AQ-280 | AQ-280 | Phase 1 Clinical | Aqilion AB | Eosinophilic Esophagitis | Details |
| PG-018 | PG-018 | Phase 1 Clinical | Prime Gene Therapeutics Co Ltd | Glomerulonephritis, Membranous; Nephrosis | Details |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
| LBG-1600M | Phase 1 Clinical | Suzhou Longbotai Pharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| NIP-046 | NIP-046 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Arthritis, Rheumatoid; Chronic Urticaria | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Filgotinib Maleate | G-146034; GLPG-0634; G-146034-101; GS-6034 | Approved | Galapagos Nv | Jyseleca | EU | Arthritis, Rheumatoid | Galapagos Nv | 2020-09-24 | Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Behcet Syndrome; Colitis, Ulcerative; Crohn Disease; Glomerulonephritis, Membranous; Immunoglobulin G4-Related Disease; Inflammatory Bowel Diseases; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Myositis; Renal Insufficiency; Sjogren's Syndrome; Spondylitis, Ankylosing; Uveitis | Details |
| Deuterated ruxolitinib | CTP-543; C-21543 phosphate; CTP-543 phosphate | Approved | Concert Pharmaceuticals Inc | LEQSELVI | United States | Alopecia Areata | Sun Pharmaceutical Industries Ltd | 2024-07-25 | Alopecia Areata; Hepatic Insufficiency; Renal Insufficiency | Details |
| Peficitinib | ASP-015K; JNJ-54781532 | Approved | Astellas Pharma Inc | Smyraf, 施觅福 | Japan | Arthritis, Rheumatoid | Astellas Pharma Inc | 2019-03-29 | Arthritis, Rheumatoid; Colitis, Ulcerative; Psoriasis | Details |
| Momelotinib Dihydrochloride | CYT-387; GS-0387; GSK-3070785 | Approved | Cytopia Pty Ltd, Gilead Sciences Inc | Ojjaara, Omjjara | United States | Primary Myelofibrosis; Anemia | Glaxosmithkline Llc, Glaxosmithkline Plc | 2023-09-15 | Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Pancreatic Intraductal Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Splenomegaly; Thrombocythemia, Essential; VEXAS Syndome | Details |
| Ivarmacitinib sulfate | SHR-0302; ARQ-252; ARQ-255 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾速达 | Mainland China | Spondylitis, Ankylosing | Jiangsu Hengrui Medicine Co Ltd | 2025-03-18 | Alopecia Areata; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Eczema; Graft vs Host Disease; Hepatic Insufficiency; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Peripheral; Metastatic breast cancer; Non-radiographic axial spondyloarthritis; Sedation; Solid tumours; Spondylarthritis; Spondylitis, Ankylosing; Triple Negative Breast Neoplasms; Vitiligo | Details |
| Gecacitinib Hydrochloride | ZG-0128; ZG-0163 | Approved | Suzhou Zelgen Biosciences Co Ltd | 泽普平 | Mainland China | Primary Myelofibrosis | Suzhou Zelgen Biopharmaceuticals Co Ltd | 2025-05-27 | Alopecia Areata; Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19); Dermatitis, Atopic; Graft vs Host Disease; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Lupus Erythematosus, Systemic; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Plaque psoriasis; Pneumonia; Polycythemia Vera; Primary Myelofibrosis; Solid tumours; Spondylitis, Ankylosing; Thrombocythemia, Essential; Vitiligo | Details |
| Abrocitinib | PF-4965842; PF-04965842 | Approved | Pfizer Inc | Cibinqo, CIBINQO, 希必可 | United Kingdom | Dermatitis, Atopic | Pfizer Inc | 2021-09-09 | Alopecia Areata; Dermatitis; Dermatitis, Atopic; Eczema; Fatigue; Food Hypersensitivity; Genetic Diseases, Inborn; Granuloma Annulare; Hepatic Insufficiency; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Plaque psoriasis; Post-Acute COVID-19 Syndrome; Prurigo; Prurigo Nodularis; Pruritus; Renal Insufficiency; Sarcoidosis; Skin Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic | Details |
| Tofacitinib Citrate | CP-690550-10; CKD-374; Tasocitinib; CP-690550; AC-1101; IMG 003 | Approved | Pfizer Inc | Jakvinus, Xeljanz, 尚杰 | United States | Arthritis, Rheumatoid | Pf Prism Cv | 2012-11-06 | Alopecia; Alopecia Areata; Amyotrophic Lateral Sclerosis; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Depression; Dermatitis; Dermatitis, Atopic; Dermatomyositis; Down Syndrome; Dry Eye Syndromes; Eczema; Gastrointestinal Diseases; Glioblastoma; Granuloma Annulare; Granulomatous Disease, Chronic; Hepatic Insufficiency; Hidradenitis Suppurativa; Inflammation; Keratoconjunctivitis Sicca; Kidney Failure, Chronic; Lung Diseases, Interstitial; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Plaque psoriasis; Pneumonia; Psoriasis; Rejection of renal transplantation; Renal Insufficiency; Sacroiliitis; Sarcoidosis; Sarcoidosis, Pulmonary; Scleritis; Scleroderma, Systemic; Sjogren's Syndrome; Spondylitis; Spondylitis, Ankylosing; Uveitis; Vitiligo | Details |
| Golidocitinib | NC-0322; AZD-4205; DZD-4205 | Approved | Astrazeneca Plc, Dizal (Jiangsu) Pharmaceutical Co Ltd | 高瑞哲 | Mainland China | Lymphoma, T-Cell, Peripheral | Dizal (Jiangsu) Pharmaceutical Co Ltd | 2024-06-18 | Anemia, Aplastic; Carcinoma, Non-Small-Cell Lung; Epstein-Barr Virus Infections; Hematologic Diseases; Histiocytosis; Lung Neoplasms; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Small Cell Lung Carcinoma; Virus Diseases | Details |
| Upadacitinib Oral Solution(艾伯维) | Approved | Abbvie Inc | RINVOQ® LQ, RINVOQ LQ, Rinvoq Lq | United States | Dermatitis, Atopic; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Non-radiographic axial spondyloarthritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Psoriatic | Abbvie Inc | 2024-04-26 | Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Non-radiographic axial spondyloarthritis; Polyarticular Juvenile Idiopathic Arthritis; Spondylitis, Ankylosing | Details | |
| Upadacitinib | ABT-494 | Approved | Abbott Laboratories | Rinvoq, Rinvoq Lq, RINVOQ LQ, 瑞福 | United States | Arthritis, Rheumatoid | Abbvie Inc | 2019-08-16 | Alopecia Areata; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Behcet Syndrome; Blepharitis; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Giant Cell Arteritis; Hidradenitis Suppurativa; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Non-radiographic axial spondyloarthritis; Sleep Wake Disorders; Spondylarthritis; Spondylitis, Ankylosing; Takayasu Arteritis; Vitiligo | Details |
| Baricitinib | LY-3009104; INCB-028050 | Approved | Incyte Corp | 艾乐明, Olumiant | EU | Arthritis, Rheumatoid | Eli Lilly Nederland BV | 2017-02-13 | Acute Lung Injury; Aicardi Goutieres syndrome; Alopecia Areata; Anhedonia; Arthritis, Juvenile; Arthritis, Rheumatoid; Cerebral Hemorrhage; Cholangitis, Sclerosing; Conjunctivitis; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Depression; Depressive Disorder, Major; Dermatitis, Atopic; Dermatomyositis; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Graft vs Host Disease; Hepatic Insufficiency; HIV Infections; Infections; Job Syndrome; Lichen Planus; Lichen Planus, Oral; Liver Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lupus Vulgaris; Malignant Atrophic Papulosis; Myositis; Nephritis; Pemphigoid, Benign Mucous Membrane; Polymyalgia Rheumatica; Post-Acute COVID-19 Syndrome; Psoriasis; Pyoderma; Pyoderma Gangrenosum; Renal Insufficiency, Chronic; Sarcoidosis; Scleroderma, Diffuse; Severe Acute Respiratory Syndrome; Skin Diseases; Skin Diseases, Papulosquamous; Skin Ulcer; Vitiligo; Wounds and Injuries | Details |
| Ruxolitinib Phosphate | INCB-18424; RUX; INCB 018424 phosphate; INCB-018424; INC-424; INCB-424 | Approved | Incyte Corp | OPZELURA, Jakavi, Jakafi | United States | Primary Myelofibrosis | Incyte Corp | 2011-11-16 | Alopecia Areata; Anemia, Aplastic; Anemia, Sickle Cell; Arthritis, Rheumatoid; Autoimmune Lymphoproliferative Syndrome; beta-Thalassemia; Bone Marrow Neoplasms; Breast Carcinoma In Situ; Breast Neoplasms; Cachexia; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Castleman Disease; Chronic eosinophilic leukemia (CEL); Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Cytokine Release Syndrome; Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilia; Exanthema; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hepatomegaly; Hidradenitis Suppurativa; HIV Infections; Hodgkin Disease; Hypereosinophilic Syndrome; Hyperplasia; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Leukemia, Neutrophilic, Chronic; Leukemia | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland